Quick answer: the so-called FDA peptide ban was not lifted in 2026. On April 15, 2026, FDA said it would remove 12 peptides, including BPC-157, TB-500 and Semax, from its Category 2 “significant safety risk” list after their nominators withdrew them, effective about April 22, 2026.[2][5] Removal is not approval, and none of the 12 became eligible for routine compounding. In July 2026 an FDA advisory committee voted to recommend six of seven reviewed peptides for the 503A bulks list, but FDA has not finalized any of them.[7]
This page explains what Category 2 is, what changed and when, and what it means for patients. For the full sequence of events, see our FDA peptide regulation timeline, and for the enforcement side, the FDA peptide compounding crackdown. Our FDA & Regulation hub collects every related guide.
What the “FDA peptide ban” actually was
There was never a single law banning peptides. The “ban” refers to how FDA sorted peptides nominated for compounding under section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act).
Under section 503A, a state-licensed pharmacy may compound with a bulk drug substance only if it meets one of three tests: it has a USP or National Formulary monograph, it is a component of an FDA-approved drug, or it appears on FDA’s 503A bulks list, which is created by regulation.[4] Most popular “wellness” peptides meet none of these tests.
While FDA works through nominations for that list, its interim policy (finalized January 2025) sorts nominated substances into three groups:[3]
| Category | Meaning | FDA enforcement stance |
|---|---|---|
| Category 1 | Under evaluation, no significant safety risk identified yet | FDA generally does not act against compounding while it evaluates |
| Category 2 | Raises significant safety risks | No enforcement discretion |
| Category 3 | Nominated without adequate support | No enforcement discretion |
Being placed in Category 2 is what people called the peptide ban.
The 2023 Category 2 placements
In 2023, FDA moved a group of peptides into Category 2. Its public safety page cites concerns such as immunogenicity (the risk of an immune reaction), peptide-related impurities, difficulty characterizing the active ingredient, and very limited human safety data.[1] Several entries on that page, such as GHRP-2, GHRP-6, ipamorelin (for 503B), kisspeptin-10 and ibutamoren (MK-677), carry a placement date of September 29, 2023.[1]
Counts differ by source. Health and Human Services Secretary Robert F. Kennedy Jr. has spoken of 19 reclassified peptides, while a law firm review noted that FDA’s own records showed 17 designations.[8]
FDA’s Pharmacy Compounding Advisory Committee (PCAC) also reviewed several peptides in late 2024. On December 4, 2024, it voted 4 to 17 against adding thymosin alpha-1 to the 503A list, 0 to 12 against AOD-9604, and 0 to 13 (or 1 to 12 for one salt form) against CJC-1295.[6]
The April 2026 removals: exact names and dates
FDA updated its 503A category list on April 15, 2026, with removal from Category 2 taking effect after 7 days, around April 22, 2026.[5] The reason given was procedural: the nominators withdrew their nominations. The 12 substances were:[5]
| Peptide | Our profile | Next step announced |
|---|---|---|
| BPC-157 | BPC-157 | PCAC, July 23, 2026 |
| KPV | KPV | PCAC, July 23, 2026 |
| TB-500 (thymosin beta-4 fragment) | TB-500 | PCAC, July 23, 2026 |
| MOTs-C | MOTS-c | PCAC, July 23, 2026 |
| Emideltide (DSIP) | DSIP | PCAC, July 24, 2026 |
| Semax | Semax | PCAC, July 24, 2026 |
| Epitalon | Epitalon | PCAC, July 24, 2026 |
| Cathelicidin LL-37 | LL-37 | PCAC before end of Feb 2027 |
| Dihexa acetate | Dihexa | PCAC before end of Feb 2027 |
| GHK-Cu (injectable routes) | GHK-Cu | PCAC before end of Feb 2027 |
| PEG-MGF | PEG-MGF | PCAC before end of Feb 2027 |
| Melanotan II | Melanotan II | PCAC before end of Feb 2027 |
GHK-Cu for non-injectable routes was handled separately. FDA removed it from Category 1 on April 22, 2026, then said on its May 14, 2026 list that it would add it back after one nominator clarified it had meant to withdraw only the injectable nomination.[2]
FDA’s public safety page now lists 17 peptides as “nominated but withdrawn,” which includes substances withdrawn before 2026 such as AOD-9604, CJC-1295, Selank and thymosin alpha-1.[1] That is why you may see both 12 and 17 quoted.
What removal does and does not mean
What it does: FDA no longer lists these 12 as nominated substances raising significant safety risks.
What it does not do:
- It is not FDA approval. None of the 12 is an approved drug, and none has been reviewed by FDA for safety and effectiveness for any use.
- It does not move them into Category 1. FDA’s announcement did not place them there, so the interim policy’s enforcement discretion does not cover them.[3][5]
- It does not make them lawful 503A ingredients. A pharmacy still needs a USP monograph, an approved-drug component, or a listing on the 503A bulks list. None of the 12 meets those tests today.[4]
- It does not change the rules for “research use only” sellers, who are outside the compounding framework entirely.
For more on the difference between local pharmacies and outsourcing facilities, see 503A vs 503B compounding. For BPC-157 in particular, see BPC-157 legal status.
The July 2026 advisory committee votes
FDA’s Federal Register notice of April 16, 2026 set PCAC meetings for July 23 and 24, 2026, under docket FDA-2025-N-6895. It listed the uses FDA reviewed: ulcerative colitis for BPC-157, wound healing and inflammatory conditions for KPV, wound healing for TB-500, obesity and osteoporosis for MOTs-C, opioid withdrawal, chronic insomnia and narcolepsy for emideltide, cerebral ischemia, migraine and trigeminal neuralgia for Semax, and insomnia for epitalon.[4]
FDA’s own briefing document proposed that none of the seven, in either salt form, be added to the list.[9] The committee voted otherwise for six of them, as reported by Healio:[7]
| Peptide | Reported vote (yes–no–abstain) | Outcome |
|---|---|---|
| BPC-157 | 8–6–1 | Recommended |
| KPV | 8–6–1 | Recommended |
| TB-500 | 8–6–1 | Recommended |
| MOTS-c | 7–5–2 | Recommended |
| Semax | 8–5–1 | Recommended |
| Epitalon | 7–4–1 | Recommended |
| Emideltide (DSIP) | 6–7–1 | Not recommended |
Other outlets reported slightly different tallies, for example 7–5 for epitalon. FDA’s official summary minutes are the final word, and we will update this table when they are posted.
What this means for you
If you see a clinic or website saying “the FDA peptide ban is over” or “FDA approved BPC-157,” that is not accurate as of October 2026. The legal status of each peptide is still unsettled, and product quality outside FDA-regulated channels is unknown. Talk with a licensed clinician about approved alternatives for your condition, and check our peptide legal status guide for the wider picture.
This is general information, not legal advice. Rules in this area are changing quickly, so check FDA’s compounding pages for the latest status.
